Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 40 years, covering the drug development process from early screening through regulatory submission.

Porsolt provides discovery and preclinical services (safety & efficacy) including in vitro assays, pathophysiological models in multiple species and cell lines, customized procedures, and tailored solutions. They offer to support drug development using high throughput screening, high content analysis, and high content histology platforms, drug formulation analysis, and bioanalytical services.

Their vast expertise covers the following areas: psychiatric and neurological disorders, cardiac and vascular diseases, oncology, pain, inflammation, gastrointestinal disorders, liver diseases, metabolic and eating disorders, respiratory diseases, dermatology, medical devices, and predictive toxicity of compounds.

–  Therapeutic areas: Cardiovascular System, Central Nervious System,Dermatology,Gastrointestinal System,Histoilogy, Inflammation, Liver & Hepatic System,Medical Devices,Obesity & Metabolic Disorders, Oncology,Pain, Pharmacokinetics, Predictive Toxicity, Respiratory System, Safety Regulatory Package, Thrombosis/ Blood, Urogenital System,Biomarkers Assays, Cell & Tissue Banks,Formulation Analysis, Image Processing & Data Analysis,Technical Skills,Technical Capabilities.

–  Based in: Le Genest Saint Isle (FRANCE)

–  Employees: 51 – 200

–  Created in: 1940